Abbott Laboratories has received U.S. FDA clearance and the European Union CE Mark for its Ultreon 3.0 AI-powered coronary imaging platform [1].
The approval allows physicians to use artificial intelligence to automate the analysis of artery images, which can lead to more precise stent placement during critical heart procedures.
The Ultreon 3.0 platform utilizes optical coherence tomography, or OCT, to capture high-resolution images of the coronary arteries [2]. By integrating these images with AI-driven analytics, the system provides clinicians with automated insights and real-time planning guidance during percutaneous coronary interventions [2]. This technology is the first OCT system in both the U.S. and Europe to combine high-resolution imaging with AI insights [3].
Regulatory clearance for both the FDA and the CE Mark was granted on April 28, 2024 [1], [4]. The system is designed to reduce the manual effort required to interpret complex imaging data during a procedure.
"The next-generation Ultreon 3.0 platform combines high-resolution OCT imaging with AI-driven analytics to help physicians make more precise decisions during PCI," an Abbott spokesperson said [2].
Precise stent placement is critical to preventing complications and improving long-term patient outcomes. By providing a more accurate map of the artery, the AI tool aims to minimize errors in sizing and positioning the stent within the vessel.
"Our AI-powered platform provides clinicians with real-time guidance to improve outcomes for patients undergoing coronary stent placement," an Abbott spokesperson said [5].
“The Ultreon 3.0 platform uses AI-driven analytics to provide real-time guidance for coronary artery stent placement.”
The integration of AI into optical coherence tomography represents a shift toward 'intelligent' surgical guidance, moving from purely visual data to actionable, automated analytics. By securing simultaneous approval in the U.S. and EU, Abbott is positioning the Ultreon 3.0 as a global standard for percutaneous coronary interventions, potentially reducing the margin of human error in stent placement.
